8-K: Biotricity Secures $500,000 in Private Placement, Potential for Additional $1.5 Million

Biotricity Inc. has entered into a securities purchase agreement for a private placement of convertible preferred stock, raising an initial $500,000 with the possibility of up to $1.5 million more.

Summary

• Biotricity Inc. has secured a $500,000 investment through a private placement with an institutional investor.
• The company issued 55 shares of Series B Convertible Preferred Stock at $9,090.91 per share.
• There is a potential for additional closings before December 31, 2024, where the investor may purchase up to 165 more shares for a total of $1.5 million.
• The Series B Preferred Stock has a stated value of $10,000 per share and ranks senior to all common stock regarding dividends and liquidation payments.
• Holders of the Series B Preferred Stock are entitled to cumulative dividends at an annual rate of 8%, increasing to 15% upon a triggering event.
• The initial conversion price for the preferred stock to common stock is $3.50, subject to adjustments.
• The company is required to seek stockholder approval for the conversion of the preferred stock if it exceeds 19.9% of the outstanding common stock.
• A voting agreement has been entered into with certain stockholders to ensure the approval of the conversion of the preferred stock.

Sentiment

Score: 7

Explanation: The document indicates a positive development for Biotricity with the successful private placement and potential for additional funding. However, the potential for dilution and the need for shareholder approval introduce some uncertainty.

Positives

• The private placement provides immediate capital of $500,000 to Biotricity.
• The potential for an additional $1.5 million in funding offers further financial flexibility.
• The terms of the Series B Preferred Stock include a cumulative dividend, providing a return for investors.
• The conversion feature of the preferred stock allows for potential future equity upside for the investor.
• The voting agreement with existing stockholders increases the likelihood of obtaining necessary approvals.

Negatives

• The conversion of the preferred stock to common stock could lead to dilution of existing shareholders' equity.
• The company is obligated to issue 100,000 shares of common stock to the investor if it fails to meet deadlines for filing the registration statement or having it declared effective.
• The company is required to hold multiple shareholder meetings to obtain approval for the conversion of the preferred stock if it is not approved at the first meeting.
• The conversion price of the preferred stock can be adjusted, potentially leading to further dilution.

Risks

• Failure to obtain stockholder approval for the conversion of the preferred stock could impact the company's ability to issue shares.
• The company may face challenges in meeting the deadlines for filing the registration statement and having it declared effective.
• The potential for dilution of existing shareholders' equity could negatively impact the stock price.
• The company's obligation to issue 100,000 shares of common stock for failing to meet deadlines could further dilute existing shareholders.
• The company may be required to redeem the preferred stock under certain triggering events, potentially impacting cash flow.

Future Outlook

The company may request additional closings with the investor to purchase up to an additional 165 shares of Series B Preferred Stock for gross proceeds of up to $1,500,000 before December 31, 2024. The company is also required to seek stockholder approval for the conversion of the preferred stock.

Industry Context

Private placements are a common method for companies, especially those in the growth phase, to raise capital. The use of convertible preferred stock is also a common structure, offering investors a combination of income and potential equity upside. The need for shareholder approval for conversions is a standard requirement to protect existing shareholders from excessive dilution.

Comparison to Industry Standards

• The terms of the private placement, including the purchase price, dividend rate, and conversion price, are within the typical range for similar transactions in the biotech and medical device industries.
• The use of convertible preferred stock is a common method for raising capital in this sector, as it provides investors with a degree of downside protection while still allowing for potential equity upside.
• The requirement for shareholder approval for conversions is also standard practice, as it ensures that existing shareholders have a say in any potential dilution of their equity.
• Comparable companies in the medical device space, such as iRhythm Technologies and Insulet Corporation, have also utilized private placements and convertible securities to fund their growth and development.
• The specific terms of the agreement, such as the 8% dividend rate and the $3.50 conversion price, are specific to Biotricity and reflect the company's current valuation and risk profile.

Stakeholder Impact

• Shareholders may experience dilution if the preferred stock is converted to common stock.
• The company's employees may benefit from the additional funding, which could support growth and development.
• The company's customers may benefit from the company's ability to invest in product development and innovation.
• The company's suppliers may benefit from the company's increased financial stability.

Next Steps

• The company will need to file a registration statement with the SEC for the shares issuable upon conversion of the preferred stock.
• The company will need to hold a shareholder meeting to obtain approval for the conversion of the preferred stock.
• The company may request additional closings with the investor to purchase additional shares of Series B Preferred Stock.

Key Dates

Keywords

private placement, convertible preferred stock, Series B Preferred Stock, institutional investor, stockholder approval, registration rights, dilution, voting agreement, capital raise